• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Fresenius Medical Care Listed in The Dow Jones Sustainability World Index and for the 15th Time in The Dow Jones Sustainability Europe Index

    12/23/24 9:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care
    Get the next $FMS alert in real time by email
    • Ranking puts Fresenius Medical Care among the best-in-class sustainability performers in the world and Europe
    • The company recorded progress towards its sustainability targets
    • Sustainability is one of the essential drivers for future

    BAD HOMBURG, Germany, Dec. 23, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has been recognized as a sustainability leader with the inclusion in the Dow Jones Sustainability World Index and with the inclusion in the Dow Jones Sustainability Europe Index for the 15th time. Dow Jones Sustainability Index (DJSI) is one of the world's leading ESG (Environmental, Social, Governance) stock indices.

    Fresenius Medical Care Listed in The Dow Jones Sustainability World Index and for the 15th Time in The Dow Jones Sustainability Europe Index

    Helen Giza, CEO of Fresenius Medical Care AG, said: "We believe that sustainability and excellent patient care are inextricably linked. I am very proud that our employees' commitment to our sustainability efforts has been recognized through the inclusion in the indices. Considering sustainability in our products and the way we work helps to ensure that we provide excellent, high-quality services for future generations."

    Fresenius Medical Care continuously incorporates sustainability into its global business operations. The company's approach centers on three strategic focus areas:

    • Enhancing quality of care and access to healthcare,
    • building the best teams to serve patients, and
    • reducing the company's environmental footprint.

    In 2023, FME has reported progress toward its sustainability targets and governance:

    • Fresenius Medical Care improved its Net Promoter Score to 72, reflecting a high patient satisfaction with its services.
    • The company increased the share of women in the top two management levels below Management Board to 34%, underlining its commitment to diversity, equity and inclusion.
    • FME moved ahead with its climate neutrality action plan, with Scope 1 and 2 emissions in 2023 decreasing by 16% from a 2020 baseline. The reduction of CO2e emissions is included in the targets for the long-term compensation of the Management Board members for 2024.
    • In 2024 the company signed five virtual power purchase agreements for approximately 580 gigawatt hours per year with wind and solar farms in Germany and the U.S. It also submitted the commitment letter to the Science Based Target initiative (SBTi).

    The Dow Jones Sustainability Indices are the longest-running global sustainability benchmarks. Each year, over 13,000 companies are invited to participate in the Corporate Sustainability Assessment (CSA). Approximately 3,500 of the largest companies worldwide are eligible for inclusion in any DJSI. The annual review evaluates companies' sustainability performance in areas relevant to each industry.

    An overview of Fresenius Medical Care's progress in sustainability can be found in the company's non-financial group report here.

    About Fresenius Medical Care:

    Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.1 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,732 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 308,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

    For more information visit the company's website at www.freseniusmedicalcare.com.

    Disclaimer:

    This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

    Media contact

    Christine Peters

    T +49 160 60 66 770

    [email protected]

    Contact for analysts and investors

    Dr. Dominik Heger

    T +49 6172 609 2601

    [email protected]

    www.freseniusmedicalcare.com

    Fresenius Medical Care starts the year with strong earnings growth (PRNewsfoto/Fresenius Medical Care North Am)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-listed-in-the-dow-jones-sustainability-world-index-and-for-the-15th-time-in-the-dow-jones-sustainability-europe-index-302338375.html

    SOURCE Fresenius Medical Care Holdings, Inc.

    Get the next $FMS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $FMS

    DatePrice TargetRatingAnalyst
    12/2/2024Underperform → Neutral
    BofA Securities
    11/6/2024$25.60Buy
    Berenberg
    1/8/2024Equal-Weight → Underweight
    Morgan Stanley
    11/24/2023Reduce → Hold
    HSBC Securities
    11/17/2023Hold → Buy
    Societe Generale
    8/14/2023Buy → Neutral
    UBS
    8/1/2023Neutral
    Citigroup
    7/12/2023Buy
    Goldman
    More analyst ratings

    $FMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fresenius Medical Care Collaborates with Coordination of National Institutes of Health and Specialty Hospital to Extend Access to Innovative Dialysis Therapy in Mexico

      High-Volume Hemodiafiltration is used for the first time in seven out of 10 CCINSHAE centers in MexicoIn Mexico, 240 CCINSHAE patients are now being treated; more than 410 regular patients also treatedFresenius Medical Care is committed to expanding HighVolumeHDF therapy to all markets where it is not already present, including the United StatesBAD HOMBURG, Germany, July 3, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, will extend High-Volume Hemodiafiltration (HighVolumeHDF) access for patients in seven out of 10 centers in Mexico, by partnering with the country's Coordination of National Institu

      7/3/25 8:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical Care Launches its Strategy FME Reignite with increased Profitability Aspirations, and a New Capital Allocation Framework to further enhance Value Creation

      FME Reignite sets the ambition to lead kidney care through exceptional patient care and innovationThe Company will set the new standard of care in the U.S. with the introduction of the 5008X dialysis machine and unveils launch plansProfitability aspirations set for 2030 to advance to mid-teens percent industry-leading operating income1 marginsFME25+ savings target expanded by EUR 300 million to EUR 1.05 billion by 2027Annual capex of EUR 0.8 to 1.0 billion for core business to drive profitable growth and to support innovationFurther optimization of capital structure with lowered net leverage ratio target band of 2.5x to 3.0xCommitment to return excess capital to shareholders: 30-40 percent d

      6/17/25 7:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical Care Begins Broader U.S. Commercialization of 5008X™ CAREsystem, Achieves Key Milestones in Efforts to Introduce High-Volume Hemodiafiltration Dialysis Therapy to Individuals with Kidney Disease in the U.S.

      Updated 5008X CAREsystem with Additional Features Receives FDA 510(k) ClearanceCompany announces first wave of Fresenius Kidney Care clinics in the U.S. to begin offering  high-volume hemodiafiltration therapy to dialysis patientsIntroducing the 5008X CAREsystem and hemodiafiltration kidney replacement therapy is a key pillar of the company's growth strategyBAD HOMBURG, Germany, June 4, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today begins the second phase of the company's efforts to introduce high-volume hemodiafiltration (HVHDF) kidney replacement therapy across the United States. The compa

      6/4/25 8:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care

    $FMS
    SEC Filings

    See more
    • SEC Form 11-K filed by Fresenius Medical Care AG

      11-K - Fresenius Medical Care AG (0001333141) (Filer)

      6/27/25 1:51:36 PM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 6-K filed by Fresenius Medical Care AG

      6-K - Fresenius Medical Care AG (0001333141) (Filer)

      6/17/25 3:18:39 PM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 6-K filed by Fresenius Medical Care AG

      6-K - Fresenius Medical Care AG (0001333141) (Filer)

      6/5/25 9:49:29 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care

    $FMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Fresenius Medical upgraded by BofA Securities

      BofA Securities upgraded Fresenius Medical from Underperform to Neutral

      12/2/24 8:51:34 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Berenberg initiated coverage on Fresenius Medical with a new price target

      Berenberg initiated coverage of Fresenius Medical with a rating of Buy and set a new price target of $25.60

      11/6/24 6:26:23 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical downgraded by Morgan Stanley

      Morgan Stanley downgraded Fresenius Medical from Equal-Weight to Underweight

      1/8/24 7:47:44 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care

    $FMS
    Leadership Updates

    Live Leadership Updates

    See more
    • Fresenius Medical Care appoints Jörg Häring as new Management Board member responsible for Legal, Compliance and Human Resources

      Effective June 1, the Legal, Compliance, and Human Resources functions will be combined in a new Management Board roleJörg Häring contributes his extensive expertise from the energy, industry, and healthcare sectorsBAD HOMBURG, Germany, March 13, 2024 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has announced today the appointment of Jörg Häring (54) as its new Global Head of Legal, Compliance and Human Resources. Häring, who will join the company as a member of the Management Board, will start on June 1, 2024, and also assume the role of Labor Director.

      3/13/24 10:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical Care AG nominates Six Employee Representatives to the Supervisory Board

      BAD HOMBURG, Germany, Feb. 5, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has nominated six employee representatives as members of the company's Supervisory Board. Effective January 26, the competent court approved the company's application for the judicial appointment of the six employee representatives. The judicial appointment will remain effective until completion of the election of employee representatives by the FME workforce located in Germany.   Fresenius Medical Care succ

      2/5/24 8:57:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical Care simplifies corporate structure by converting into a German stock corporation

      Extraordinary General Meeting approves conversion of Fresenius Medical Care's legal formSeveral advantages including faster and more agile decision-makingMichael Sen elected as Chair of new Supervisory BoardConversion expected to be completed by the end of 2023WALTHAM, Mass., July 14, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, held an Extraordinary General Meeting (EGM) today. The Company's shareholders approved all agenda items with large majority, including the conversion of Fresenius Medical Care from the legal form of a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA) into a

      7/14/23 11:34:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care

    $FMS
    Financials

    Live finance-specific insights

    See more
    • Fresenius Medical Care Launches its Strategy FME Reignite with increased Profitability Aspirations, and a New Capital Allocation Framework to further enhance Value Creation

      FME Reignite sets the ambition to lead kidney care through exceptional patient care and innovationThe Company will set the new standard of care in the U.S. with the introduction of the 5008X dialysis machine and unveils launch plansProfitability aspirations set for 2030 to advance to mid-teens percent industry-leading operating income1 marginsFME25+ savings target expanded by EUR 300 million to EUR 1.05 billion by 2027Annual capex of EUR 0.8 to 1.0 billion for core business to drive profitable growth and to support innovationFurther optimization of capital structure with lowered net leverage ratio target band of 2.5x to 3.0xCommitment to return excess capital to shareholders: 30-40 percent d

      6/17/25 7:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical Care Annual General Meeting: Strong Performance Against Its Strategic Plan Results in Highest Dividend per Share in Its History

      Shareholders approved the proposed dividend of 1.44 Euro per share, representing a 21 percent increase year-over-year and marking the highest dividend in the company's historyExcellent progress in the company's transformation and turnaround plans continues to strengthen the foundation for sustainable, profitable growthIn 2024, organic revenue growth1 was 4 percent, and operating income increased by 18 percent on an outlook base2, coming in at the upper end of the company's outlookThe company is well positioned for double digit earnings growth in 2025, translating to an 11-12 percent marginBAD HOMBURG, Germany, May 22, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading pro

      5/22/25 11:45:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical Care starts 2025 with strong organic revenue and income growth

      Strong organic revenue growth1 of 5% driven by Care Enablement and Care DeliveryStable U.S. same market treatment development despite impact from a severe flu seasonFME25 savings of EUR 68 million contributed to earningsOperating income2 grew 11% at constant currency resulting in margin expansionReported operating income grew by 35% and reported net income3 by 113%Net leverage ratio further improved to 2.8x and FY 2025 outlook confirmedBAD HOMBURG, Germany, May 6, 2025 /PRNewswire/ -- "The results of the first quarter of 2025 once again demonstrate our continuous operational and financial progress as we are executing the third and last year of our current strategic plan," said Helen Giza, Ch

      5/6/25 7:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care

    $FMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Fresenius Medical Care AG

      SC 13G - Fresenius Medical Care AG (0001333141) (Subject)

      11/14/24 4:08:53 PM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by Fresenius Medical Care AG (Amendment)

      SC 13G/A - Fresenius Medical Care AG (0001333141) (Subject)

      2/13/24 1:36:58 PM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13D/A filed by Fresenius Medical Care AG (Amendment)

      SC 13D/A - Fresenius Medical Care AG (0001333141) (Subject)

      12/7/23 11:45:52 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care